The company

Censo is a world leader in the creation and use of induced Pluripotent Stem Cells (iPSCs) for drug discovery.  We provide contract research services to leading pharmaceutical companies and medical research charities to support and accelerate their development of new drugs.  

Developed over the last decade, iPSC technology enables researchers to create unlimited quantities of almost any type of human cell from a small donated tissue sample.  As the cells created all have the donor’s genome, studying how they function and respond to existing or candidate drugs provides an understanding of how cells in the donor’s own body may develop a disease and how they may respond to drugs. 

More and more researchers recognise that iPSC technology offers a new means for lab-based testing of drugs using human cells.  It is particularly valuable to investigate diseases of the brain, such as Alzheimer’s, for which it is impossible to obtain tissue samples from living donors.

At Censo we have developed specialist capabilities for the investigation of neuro-inflammation and pain.  These are areas of intense commercial research, and we are working with an increasing number of clients from Europe, the US and Japan.